Literature DB >> 12594239

K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.

Joachim Diebold1, Florian Seemüller, Udo Löhrs.   

Abstract

K-RAS mutations are the most frequent molecular genetic alteration in serous ovarian tumors of borderline malignancy (SBOT). The pathogenesis of associated contralateral tumors and extraovarian implants and Müllerian inclusion cysts is obscure. We hypothesized that the comparison of K-RAS mutations in these lesions might help to distinguish multifocal from metastatic foci. Eight cases of SBOT with known K-RAS mutation (RAS+) and two cases without mutation (RAS-) were analyzed for comparison. DNA was extracted from multiple samples of 58 paraffin-embedded and laser-microdissected ovarian and extraovarian lesions (10 ovarian borderline tumors, 8 contralateral tumors, 25 implants, 15 inclusion cysts; total: 97 samples). K-RAS exon 1 was amplified by PCR and analyzed by denaturing gradient gel electrophoresis and cycle sequencing. In 12 of 14 SBOT and in 2 of 2 extraovarian implants, the K-RAS mutation could be found in different areas of the same lesion, indicating monoclonality. All RAS+ ovarian borderline tumors with contralateral tumors (six of six) harbored an identical mutation in both ovaries (in one case, a separate surface borderline tumor component contained a different mutation in addition). In 4 of 5 RAS+ ovarian tumors with extraovarian lesions, RAS mutations were also found in implants (15/21 implants [71%]) and more rarely in inclusion cysts (3 of 12 lesions [25%]). These extraovarian mutations were always identical to the one in the ovary (18 of 18 [100%]). Regarding the contralateral and extraovarian lesions of the two RAS- SBOT, only one extraovarian implant contained a RAS mutation. The demonstration of K-RAS mutations in Müllerian inclusion cysts and implants of SBOT suggests that K-RAS mutations represent a pivotal event during neoplastic transformation of ovarian and extraovarian serous epithelium. Considering our observations, the two putative pathogenetic mechanisms for the development of implants and endosalpingiosis-multifocal tumorigenesis and spread from the ovarian primary tumor-seem to coexist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594239     DOI: 10.1097/01.lab.0000056994.81259.32

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.

Authors:  Michael Herman Chui; Deyin Xing; Felix Zeppernick; Zoe Q Wang; Charlotte G Hannibal; Kirsten Frederiksen; Susanne K Kjaer; Leslie Cope; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang; Russell Vang
Journal:  Am J Surg Pathol       Date:  2019-11       Impact factor: 6.394

3.  Molecular characterization of 103 ovarian serous and mucinous tumors.

Authors:  Ildikó Vereczkey; Orsolya Serester; Judit Dobos; Mónika Gallai; Orsolya Szakács; Zoltán Szentirmay; Erika Tóth
Journal:  Pathol Oncol Res       Date:  2010-12-07       Impact factor: 3.201

Review 4.  [Serous ovarian tumors].

Authors:  J Diebold
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

5.  Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Authors:  Katherine Stemke-Hale; Kristy Shipman; Isidora Kitsou-Mylona; David G de Castro; Vicky Hird; Robert Brown; James Flanagan; Hani Gabra; Gordon B Mills; Roshan Agarwal; Mona El-Bahrawy
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

6.  Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Authors:  Laura Ardighieri; Felix Zeppernick; Charlotte G Hannibal; Russell Vang; Leslie Cope; Jette Junge; Susanne K Kjaer; Robert J Kurman; Ie-Ming Shih
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

7.  KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

Authors:  Veronika Auner; Gernot Kriegshäuser; Dan Tong; Reinhard Horvat; Alexander Reinthaller; Alexander Mustea; Robert Zeillinger
Journal:  BMC Cancer       Date:  2009-04-09       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.